IL6 and COVID-19: In our population, specific COVID-19 treatments like Dexamethasone or monoclonal antibodies directed against interleukin-6 (IL-6) or against SARS-CoV-2 Spike protein were not commonly used, mainly because severe infections were observed preferentially before these therapies were available.